A phase IIa/b study evaluating DDY391 in participants with active moderate to severe psoriatic arthritis (chinadrugtrials.org.cn) - Oct 21, 2026 - P2 | N=19 | Not yet recruiting | Sponsor: Novartis Pharma AG / Novartis (China) Biomedical Research Co., Ltd. / Catalent San Diego, Inc.
New P2 trial • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|